Milsaperidone (VHX-896) vs Olanzapine (Zyprexa)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Olanzapine (Zyprexa)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT03510325 · Phase 3 · completed

This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.

Next expected readout: February 2027 · NCT03781115 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)

Result source: NCT03510325

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Olanzapine (Zyprexa)
PANSS total, change—Not reported-8.8 vs 4.5−13.3 vs placebowk 4 · n 21NCT00686998
CGI-S, change—Not reported—Not posted · NCT00083668
PANSS response—Not reported31.7% vs 44.7%avs amisulprideNCT03510325
PSP, change—Not reported—Not posted · NCT00083668
Relapse (% of patients)—Not reported—Not posted · NCT00083668

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Olanzapine (Zyprexa)
-8.8 vs 4.5−13.3 vs placebowk 4 · n 21NCT00686998

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Olanzapine (Zyprexa)
—Not posted · NCT00083668

PANSS response

Milsaperidone (VHX-896)
—Not reported
Olanzapine (Zyprexa)
31.7% vs 44.7%avs amisulprideNCT03510325

PSP, change

Milsaperidone (VHX-896)
—Not reported
Olanzapine (Zyprexa)
—Not posted · NCT00083668

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Olanzapine (Zyprexa)
—Not posted · NCT00083668
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Olanzapine (Zyprexa): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa)
Dropout rate
63.4%Olanzapine/Intense Behavioral Weiga
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
55.9%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
38.2%
NCT00190749 · Phase 4 · registry result, not featured evidence
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0%
NCT00797277 · Phase 3 · registry result, not featured evidence
22%Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
34.2%Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
31.5%Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
18.2%
NCT00686998 · Phase 2 · registry result, not featured evidence
—Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
—3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
Discontinued due to AEs
14.9%Olanzapine/Intense Behavioral Weiga
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
18.6%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00190749 · Phase 4 · registry result, not featured evidence
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—
NCT00797277 · Phase 3 · registry result, not featured evidence
4%Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
10.5%Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
5.5%Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
4.5%
NCT00686998 · Phase 2 · registry result, not featured evidence
—Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
—3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
Serious AEs
19.8%Olanzapine/Intense Behavioral Weiga
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
12.7%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT00190749 · Phase 4 · registry result, not featured evidence
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0%
NCT00797277 · Phase 3 · registry result, not featured evidence
—Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
—Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
—Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00686998 · Phase 2 · registry result, not featured evidence
0%Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
3.2%Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
0%Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
25%0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
5.9%Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
somnolence 23.8%
weight increased 20.8%
headache 19.8%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
weight increased 30.4%
headache 18.6%
somnolence 18.6%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
weight increased 16.2%
headache 10.3%
sedation 10.3%
NCT00190749 · Phase 4 · registry result, not featured evidence
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
drowsiness 8.1%
dizziness 2.7%
NCT00797277 · Phase 3 · registry result, not featured evidence
insomnia 10%
somnolence 8%
increased appetite 6%
NCT00401973 · Phase 3 · registry result, not featured evidence
somnolence 6.6%
dry mouth 5.3%
insomnia 5.3%
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.7%
somnolence 11%
nausea 6.8%
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
weight increased 40.9% (placebo 0%)
increased appetite 18.2% (placebo 2.4%)
somnolence 18.2% (placebo 2.4%)
NCT00686998 · Phase 2 · registry result, not featured evidence
injection site irritation 6.9%
injection site pain 6.9%
psychotic disorder 6.9%
NCT06319170 · Phase 1 · registry result, not featured evidence
injection site pain 9.7%
somnolence 9.7%
blood creatine phosphokinase increased 6.5%
NCT06319170 · Phase 1 · registry result, not featured evidence
alanine aminotransferase increased 6.5%
aspartate aminotransferase increased 6.5%
somnolence 6.5%
NCT06319170 · Phase 1 · registry result, not featured evidence
3 mg
abnormal lab values 33.3%
decreased appetite 16.7%
depression 16.7%
NCT00512070 · Phase na · registry result, not featured evidence · combination
0.3 mg
abnormal lab values 50%
depression 25%
psychotic symptoms 25%
NCT00512070 · Phase na · registry result, not featured evidence · combination
abnormal lab values 29.4%
insomnia/sleep disturbance 23.5%
diarrhea 17.6%
NCT00512070 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa)

BMI 3.64 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
2.83 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
3.36 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.99 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-I 2.04 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
2.29 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Waist Circumference Change 7.22 cm @ 52wk
absolute change · cm
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
7.31 cm @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-S -2.06 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
-1.74 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
-0.17 score @ 313wk
NCT00088465 · Phase 3 · registry result, not featured evidence
BPRS-C Total -28 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-30.96 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
BPRS Total -1.98 vs -1.48 Risperidone score @ 12wk
absolute change · score
Total Score Change to Last Observation
NCT00190749 · Phase 4 · registry result, not featured evidence
CGI-S -0.22 vs -0.23 Risperidone score @ 12wk
absolute change · score
Change to last observation
NCT00190749 · Phase 4 · registry result, not featured evidence
PANSS Total 0.3 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Positive 0.21 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.08 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology 0.19 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
QLS Total 6.75 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Olanzapine (Zyprexa)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa)

BMI 3.64 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
2.83 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
3.36 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.99 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
YMRS -17.66 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-12.05 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-I 2.04 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
2.29 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Waist Circumference Change 7.22 cm @ 52wk
absolute change · cm
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
7.31 cm @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-S -2.06 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-1.74 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
BPRS-C Total -28 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-30.96 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Available safety results

Olanzapine (Zyprexa)

Dropout rate
63.4%Olanzapine/Intense Behavioral Weig
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
55.9%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Discontinued due to AEs
14.9%Olanzapine/Intense Behavioral Weig
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
18.6%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Serious AEs
19.8%Olanzapine/Intense Behavioral Weig
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
12.7%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Most frequent reported AEs
somnolence 23.8%
weight increased 20.8%
headache 19.8%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
weight increased 30.4%
headache 18.6%
somnolence 18.6%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Olanzapine (Zyprexa)'s landscape